Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Cellipont and Secretome Therapeutics are set to enter a collaboration for the manufacturing of the latter’s cellular therapy, ...

The mechanism behind β-blockers' potential in improving diastolic function in patients with HFPEF is believed to be associated with the drugs' negative chronotropic and negative inotropic ...

While HFpEF currently doesn’t have any approved ... While Tectonic Therapeutic is targeting a significant unmet medical need with a potentially best-in-class therapy, it faces the same risks ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led ...